Condition: Attention Deficit Disorder With Hyperactivity · Sponsor: Hospital de Clinicas de Porto Alegre
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
This description comes directly from the study's public registry record.
Eugênio H Grevet, MD, PhD · +55 51 3359-8094 · ehgrevet@gmail.com
Claiton HD Bau, MD, PhD · +55 51 33086718 · claiton.bau@gmail.com
Always discuss trial participation with your own doctor first.
| Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02951754